| Code | CSB-RA005508MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to IMAB027, targeting Claudin-6 (CLDN6), a tight junction protein that plays a critical role in cell-cell adhesion and epithelial barrier formation. CLDN6 exhibits highly restricted expression in normal adult tissues but is aberrantly reactivated in various malignancies, making it an attractive oncofetal antigen. This protein is particularly overexpressed in ovarian cancer, testicular germ cell tumors, endometrial cancer, and certain lung cancers, where its expression correlates with tumor progression and metastatic potential.
IMAB027, the reference antibody, is a chimeric IgG1 monoclonal antibody that has been investigated in clinical trials for CLDN6-positive solid tumors, demonstrating potential for antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mechanisms. This biosimilar provides researchers with a valuable tool for investigating CLDN6 biology, validating CLDN6 as a therapeutic target, studying tumor-specific antigen expression patterns, and exploring novel immunotherapeutic approaches in oncology research.
There are currently no reviews for this product.